Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.

Journal of proteome research - 6 Oct 2017

Thomas Stefani N, Chen Lijun, Liu Yang, Höti Naseruddin, Zhang Hui

Abstract excerpt

Approximately 20% of high-grade serous ovarian cancers are homologous-recombination (HR)-deficient due to genetic and epigenetic mutations of HR pathway genes including the tumor suppressor genes BRCA1 and 2. HR deficiency (HRD) compromises cells' ability to efficiently repair DNA damage, but it also increases sensitivity to chemotherapeutic treatment strategies; however, not all ovarian cancer patients with HRD...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acetylation
Share to BRCA1 Protein

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma

Share to Histones

Share to Homologous Recombination

Share to Lysine

Share to Protein Processing, Post-Translational

Share to Proteomics

Source

Open in PubMed Open full text

Identifiers

PMID: 28866885
DOI: 10.1021/acs.jproteome.7b00405
PMCID: PMC5630524

Genes

BRCA1
HDAC6

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 9 closest

Targeted Proteomic Analyses of Histone H4 Acetylation Changes Associated with Homologous-Recombination-Deficient High-Grade Serous Ovarian Carcinomas.PMID 28866885Read ↗

RB1 expression and HR proficiency define a poor-outcome molecular subtype of high grade serous ovarian carcinomaSemantic proximity Read ↗

Neoantigen load and HLA-class I expression identify a subgroup of tumors with a T-cell-inflamed phenotype and favorable prognosis in homologous recombination-proficient high-grade serous ovarian carcinoma.Semantic proximity Read ↗

Homologous recombination proficient subtypes of high-grade serous ovarian cancer: treatment options for a poor prognosis groupSemantic proximity Read ↗

Functional Homologous Recombination Assay on FFPE Specimens of Advanced High-Grade Serous Ovarian Cancer Predicts Clinical Outcomes.Semantic proximity Read ↗

Identification of biomarkers complementary to homologous recombination deficiency for improving the clinical outcome of ovarian serous cystadenocarcinoma.Semantic proximity Read ↗

ZC3H18 specifically binds and activates the BRCA1 promoter to facilitate homologous recombination in ovarian cancerSemantic proximity Read ↗

Orthogonal proteomic platforms and their implications for the stable classification of high-grade serous ovarian cancer subtypesSemantic proximity Read ↗

Global histone modifications in breast cancer correlate with tumor phenotypes, prognostic factors, and patient outcome.Semantic proximity Read ↗

ATM Inhibition Synergizes with Fenofibrate in High Grade Serous Ovarian Cancer CellsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.